Literature DB >> 16139000

Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy.

Ilse Krebs1, Susanne Binder, Ulrike Stolba, Carl Glittenberg, Werner Brannath, Alexandra Goll.   

Abstract

PURPOSE: To examine whether the encouraging functional results one year after photodynamic therapy (PDT) can be maintained up to three years.
DESIGN: Prospective interventional case series.
METHODS: Highly myopic eyes that had been treated with PDT for subfoveal choroidal neovascularization and had been observed at least 36 months were included. Distance acuity (Early Treatment of Diabetic Retinopathy charts), reading acuity (Jaeger charts), 10-degree static threshold perimetry, fluorescein angiography, and optical coherence tomography were performed. The main outcome measures were the differences of the values among the baseline and the month 12 and the month 36 examinations.
RESULTS: Twenty eyes of 18 patients were included: 15 patients were female, and 3 patients were male. The average age was 64 years (range, 36 to 85 years). The mean distance acuity was 43 letters at baseline and 53 letters after 12 months and after 36 months. The mean reading acuity changed from mean J10.8 to mean J8.1 after 12 months and to mean J9.85 after 3 years. The mean defect decreased from mean 13.5 dB at baseline to mean 12.5 dB after 12 months and mean 11.2 dB after 36 months. The maximum retinal thickness decreased from mean 360 mum at baseline to mean 259 mum after one year and mean 238 mum after 36 months.
CONCLUSION: Distance acuity and central visual field showed stabilization after the month 12 examination up to the month 36 examination. The reading acuity decreased between the month 12 and the month 36 examinations, which might be related to an increase of retinal atrophy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139000     DOI: 10.1016/j.ajo.2005.03.050

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

2.  Prognosis of untreated occult choroidal neovascularization.

Authors:  Ilse Krebs; Ulrike Stolba; Carl Glittenberg; Orang Seyeddain; Thomas Benesch; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-27       Impact factor: 3.117

3.  Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population.

Authors:  Leila El Matri; Fedra Kort; Ahmed Chebil; Rim Bouraoui; Ahlem Merdassi; Mejda Bouladi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-12       Impact factor: 3.117

4.  Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.

Authors:  H Sakaguchi; Y Ikuno; F Gomi; M Kamei; M Sawa; M Tsujikawa; Y Oshima; S Kusaka; Y Tano
Journal:  Br J Ophthalmol       Date:  2006-08-16       Impact factor: 4.638

Review 5.  Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Caroline Fenton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 6.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

7.  Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome.

Authors:  Jose M Ruiz-Moreno; Javier A Montero
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-10       Impact factor: 3.117

8.  Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia.

Authors:  Pukhraj Rishi; Ekta Rishi; Anusha Venkataraman; Lingam Gopal; Tarun Sharma; Muna Bhende; Dhanashree Ratra; Pratik Ranjan Sen; Parveen Sen
Journal:  Indian J Ophthalmol       Date:  2011 May-Jun       Impact factor: 1.848

9.  Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration.

Authors:  Chieko Shiragami; Masahiro Miyake; Atsushi Fujiwara; Yuki Morizane; Akitaka Tsujikawa; Ayana Yamashita; Fumio Shiraga
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 10.  Myopic choroidal neovascularisation: current concepts and update on clinical management.

Authors:  Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2014-07-01       Impact factor: 4.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.